Coventry’s Special Shareholder Meeting, Shire Partners with Boston Hospital: Healthcare Business Wrap
Coventry Health Care (NYSE:CVH) will conduct a special shareholder meeting in Nashville on Wednesday (10:00 AM), at which to consider and vote on a proposal to adopt merging Jaguar Merger Subsidiary into the company, with Coventry remaining the surviving entity.
HeartWare International (NASDAQ:HTWR), in a Tuesday release, said that it has won approval from the FDA for the HeartWare Ventricular Assist System to be used as a bridge to heart transplantation in patients having end-stage heart failure. The firm is a top innovator of less invasive, miniaturized circulatory support technologies which are revolutionizing the treatment of advanced heart failure.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Astex Pharmaceuticals (ASTX) announced Tuesday that results from the dose escalation part of a randomized Phase 1/2 first-in-human clinical trial of subcutaneous SGI-110, which is a novel hypomethylating agent, in patients suffering from relapsed/refractory intermediate or high-risk myelodysplastic syndromes or acute myelogenous leukemia will be presented at the American Society of Hematology Annual Meeting in Atlanta, on December 10th at 11:45 AM. Astex is a pharmaceutical firm that is dedicated to the discovery and development of novel small molecule therapeutics.
Shire (SHPG) said has announced that it will collaborate with Boston Children’s Hospital on researching treatments for rare pediatric diseases. Through the terms, Shire will make an initial upfront payment to the Hospital and will have the option to fund selected research programs, according to a Tuesday joint press release. The upfront payment amount was not reported.